Journal of Hepatology
Volume 44, Issue 1 , Pages 56-61, January 2006

Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis

  • Louis d'Alteroche

      Affiliations

    • Service d'Hépato-Gastroentérologie, Hôpital Trousseau, 37 044, Tours cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +332 47 47 59 65; fax: +332 47 47 84 28.
  • ,
  • Samuel Majzoub

      Affiliations

    • Service d'Ophtalmologie, Hôpital Bretonneau, Centre Hospitalier Universitaire de Tours, Tours, France
  • ,
  • Anne-Isabelle Lecuyer

      Affiliations

    • Information Médicale, Hôpital Bretonneau, Centre Hospitalier Universitaire de Tours, Tours, France
  • ,
  • Marie-Paule Delplace

      Affiliations

    • Service d'Ophtalmologie, Hôpital Bretonneau, Centre Hospitalier Universitaire de Tours, Tours, France
  • ,
  • Yannick Bacq

      Affiliations

    • Service d'Hépato-Gastroentérologie, Hôpital Trousseau, 37 044, Tours cedex, France

Received 7 February 2005; received in revised form 13 July 2005; accepted 15 July 2005. published online 22 August 2005.

Background/Aims

Ophthalmologic side effects have been reported during interferon therapy, particularly retinal lesions and neurovisual impairment. The aim of this prospective study was to assess the nature and the frequency of such lesions during alpha-interferon therapy for viral hepatitis.

Methods

Between 1995 and 2003, 156 patients treated with standard or pegylated alpha-interferon, with or without ribavirin, had a regular ophthalmologic examination before and during treatment. No patient had signs of retinopathy before treatment. Cotton-wool spots were found in 31 patients and retinal hemorrhage in nine patients during treatment (24% of patients). These lesions remained asymptomatic and disappeared in all patients. A previous history of arterial hypertension (RR 4.60, 95% CI 1.95–10.85), age above 45 years (RR 2.80, 95% CI 1.36–5.85), and use of pegylated alpha-interferon (RR 2.75, 95% CI 1.41–5.38) were significantly associated with retinopathy. Neurovisual impairment was present in 31 patients (20%) before treatment and in 74 patients (47%) during treatment.

Conclusions

In conclusion, this study showed that signs of retinopathy and neurovisual impairment were common in patients receiving alpha-interferon therapy but were rarely symptomatic. It suggests that alpha-interferon may usually be continued in asymptomatic patients as long as there is careful fundoscopic examination.

Keywords: Interferon, Side-effects, Cotton-wool spots, Retinal hemorrhage, Visual evoked response

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 ☆The authors who have taken part in this study declared that they have not a relationship with the manufacturers of the drugs involved either in the past or present and did not receive funding from the manufacturers to carry out their research.

PII: S0168-8278(05)00517-9

doi:10.1016/j.jhep.2005.07.026

Journal of Hepatology
Volume 44, Issue 1 , Pages 56-61, January 2006